In a global Phase 3 trial, gotistobart showed promising results in patients with squamous non-small cell lung cancer. The study revealed a reduction in the risk of death by more than half compared to standard chemotherapy, with a manageable safety profile. The median overall survival with gotistobart has not been reached at nearly 15 months follow-up, compared to 10 months with chemotherapy. This chemotherapy-free treatment has the potential to be an alternative for those with high unmet medical needs. The trial is ongoing, with encouraging results presented at a recent lung cancer conference in Chicago.

Read more at GlobeNewswire: BioNTech and OncoC4 Announce Clinically Meaningful Overall